Michael Schmidt
Stock Analyst at Guggenheim
(4.78)
# 98
Out of 5,242 analysts
132
Total ratings
61.32%
Success rate
48.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Downgrades: Neutral | n/a | $1.73 | - | 1 | May 8, 2026 | |
| ONC BeOne Medicines AG | Maintains: Buy | $410 → $420 | $309.62 | +35.65% | 6 | May 7, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $175 → $205 | $153.73 | +33.35% | 7 | May 7, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $6 → $10 | $4.14 | +141.55% | 5 | Apr 10, 2026 | |
| NBTX Nanobiotix | Maintains: Buy | $26 → $36 | $40.18 | -10.40% | 4 | Apr 2, 2026 | |
| CMPX Compass Therapeutics | Reiterates: Buy | $12 | $1.93 | +521.76% | 6 | Mar 24, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $10 → $15 | $3.76 | +298.94% | 3 | Mar 18, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $34 → $30 | $18.88 | +58.90% | 3 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Buy | $12 → $20 | $11.61 | +72.34% | 2 | Mar 16, 2026 | |
| XFOR X4 Pharmaceuticals | Initiates: Buy | $12 | $4.04 | +197.03% | 1 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $20 | $21.62 | -7.49% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $27.05 | +47.87% | 4 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $35 | $22.96 | +52.44% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.16 | +188.46% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $125 | $97.41 | +28.32% | 7 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.40 | +194.12% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $8.46 | +112.77% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $9.10 | +64.84% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $32.58 | -47.82% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $27.00 | +66.67% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $29.88 | -49.80% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $80.61 | -35.49% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $13.66 | -26.79% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $19.77 | +61.86% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $4.27 | +227.87% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $27.99 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $49.65 | -15.41% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.27 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.97 | +302.41% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.00 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $7.89 | +1,319.52% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.59 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.22 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.96 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $11.27 | +201.69% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.45 | +961.22% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.52 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $28.79 | +177.87% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.20 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.44 | +23.87% | 2 | Nov 7, 2017 |
enGene Therapeutics
May 8, 2026
Downgrades: Neutral
Price Target: n/a
Current: $1.73
Upside: -
BeOne Medicines AG
May 7, 2026
Maintains: Buy
Price Target: $410 → $420
Current: $309.62
Upside: +35.65%
Revolution Medicines
May 7, 2026
Maintains: Buy
Price Target: $175 → $205
Current: $153.73
Upside: +33.35%
Zentalis Pharmaceuticals
Apr 10, 2026
Maintains: Buy
Price Target: $6 → $10
Current: $4.14
Upside: +141.55%
Nanobiotix
Apr 2, 2026
Maintains: Buy
Price Target: $26 → $36
Current: $40.18
Upside: -10.40%
Compass Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $12
Current: $1.93
Upside: +521.76%
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $3.76
Upside: +298.94%
Monte Rosa Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $18.88
Upside: +58.90%
Erasca
Mar 16, 2026
Maintains: Buy
Price Target: $12 → $20
Current: $11.61
Upside: +72.34%
X4 Pharmaceuticals
Mar 9, 2026
Initiates: Buy
Price Target: $12
Current: $4.04
Upside: +197.03%
Mar 6, 2026
Maintains: Buy
Price Target: $18 → $20
Current: $21.62
Upside: -7.49%
Feb 23, 2026
Maintains: Buy
Price Target: $45 → $40
Current: $27.05
Upside: +47.87%
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $22.96
Upside: +52.44%
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $4.16
Upside: +188.46%
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $97.41
Upside: +28.32%
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.40
Upside: +194.12%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $8.46
Upside: +112.77%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $9.10
Upside: +64.84%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $32.58
Upside: -47.82%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $27.00
Upside: +66.67%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $29.88
Upside: -49.80%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $80.61
Upside: -35.49%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $13.66
Upside: -26.79%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $19.77
Upside: +61.86%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $4.27
Upside: +227.87%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $27.99
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $49.65
Upside: -15.41%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.27
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $4.97
Upside: +302.41%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $30.00
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $7.89
Upside: +1,319.52%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.59
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.22
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.96
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $11.27
Upside: +201.69%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.45
Upside: +961.22%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.52
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $28.79
Upside: +177.87%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $8.20
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.44
Upside: +23.87%